Shares of Piramal Pharma Ltd slumped 5% on 19 February after the company secured six observations from the US Food and Drug Administration (USFDA).

The USFDA conducted a General GMP examination of the company’s Turbhe facility from 11 February to 17 February 2025.

After the inspection, a Form-483 was issued with six observations, the majority of which were aimed at enhancing processes and practices rather than data integrity.

The company will give the agency a comprehensive response to the aforementioned observations within the specified time limit. There is no doubt that the observations will be effectively closed, and the highest standards of compliance will be maintained.

The company assures us that it is committed to maintaining high compliance standards and has expressed its confidence in addressing the observations effectively.

Piramal Pharma (PPL), a subsidiary of the Piramal Group, operates across three key segments: contract development and manufacturing (CDMO), complex hospital generics (critical care), and consumer healthcare (OTC) products.

However, at 11:45 am, the shares of Piramal Pharma turned green and were trading 2.10% higher at Rs 201.81 on NSE.

Curious About Piramal Pharma? Ask the Analyst.

Tired of guessing stocks to trade in daily?
Unicorn Signals empowers you with powerful tools like daily stock scans for Intraday, Swing & Investing, Market Predictions and much more. Download the Unicorn Signals app today and take control of your investments!